# US 2023/0144855 A1 · Methods and compositions for inducing fetal hemoglobin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0144855 A1
- Document ID: US20230144855A1
- Status: Published application
- Kind: A1
- Application number: 17/901,371
- Filed: 2022-09-01
- Published: 2023-05-11
- Earliest claimed: 2021-09-01
- Assignees: Flagship Pioneering Innovations VI, LLC
- Applicants: Flagship Pioneering Innovations VI, LLC
- Inventors: Mauricio CORTES; Xiaoji SUN; Anthony Joseph MONTI; Nicholas McCartney PLUGIS
- Web page: https://patentgrep.com/patent/US20230144855A1

## CPC

- C12N 5/0641: {Erythrocytes}
- C40B 30/06: by measuring effects on living organisms, tissues or cells
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 2501/23: Interleukins [IL]
- C12N 2501/999: Small molecules not provided for elsewhere
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides methods for increasing the quantity and/or the ratios of erythroblasts, reticulocytes, and/or erythrocytes, or progenitors thereof, in which any of these cells express HbF (e.g. HbF+ and/or HbFhigh cells). The present disclosure further provides methods for treating diseases or disorders characterized by, for example, oxygen delivery deficiencies and/or reduced expression and/or activity of hemoglobin. Such diseases, without limitation, are mitigated by therapeutic reactivation of HbF.

## Claims

### Claim at position 1

-3. (canceled)

### Claim 4

A method for directing a change in cell state of a progenitor cell, comprising:
contacting a population of cells comprising a progenitor cell with at least one perturbagen selected from Table 3, or a variant thereof, and capable of altering a gene signature in the progenitor cell,
wherein altering the gene signature comprises an increase in expression and/or activity in the progenitor cell of one or more genes selected from the genes designated as an “up” gene in the gene directionality column of Table 1a and/or Table 2 and/or a decrease in expression and/or activity in the progenitor cell of one or more genes selected from the genes designated as a “down” gene in the gene directionality column of Table 1a and/or Table 2 and/or an increase in expression and/or activity in the progenitor cell of one or more genes selected from Table 1b and/or a decrease in expression and/or activity in the progenitor cell of one or more genes selected from Table 1b and
wherein the progenitor cell is a non-lineage committed CD34+ cell.

### Claim 5 (depends on 4)

The method of claim 4, wherein altering the gene signature comprises an increase in expression and/or activity in the progenitor cell of a network module designated in the network module column of Table 1a and/or Table 1b.

### Claim 6 (depends on 4)

The method of claim 4, wherein the change in cell state provides an increase in the number of one or more of proerythroblasts, early erythroblasts, intermediate erythroblasts, late erythroblasts, reticulocytes, and erythrocytes.

### Claim 7 (depends on 6)

The method of claim 6, wherein the change in cell state provides an increase in F cells.

### Claim 8 (depends on 6)

The method of claim 6, wherein one or more of the proerythroblasts, early erythroblasts, intermediate erythroblasts, late erythroblasts, reticulocytes, and erythrocytes expresses HBG1 and/or HBG2 and/or fetal hemoglobin (HbF).

### Claim 9 (depends on 8)

The method of claim 8, wherein the increase in the number of erythrocytes expressing HbF is relative to the number of erythrocytes obtained from a population of progenitor cells that is not contacted with the at least one perturbagen, or relative to the population of progenitor cells prior to contacting with the at least one perturbagen.

### Claim 10 (depends on 6)

The method of claim 6, wherein the change in cell state provides an increase in the number of erythrocytes expressing HbF.

### Claim 11 (depends on 4)

The method of claim 4, wherein the number of progenitor cells is decreased or increased.

### Claim 12

(canceled)

### Claim 13 (depends on 6)

The method of claim 6, wherein the number of proerythroblasts, BFU-E cells, CFU-E cells, early erythroblasts, intermediate erythroblasts, late erythroblasts, reticulocytes, and/or erythrocytes is increased after contacting the population of cells comprising a CD34+ cell with the at least one perturbagen, wherein one or more of the proerythroblasts, early erythroblasts, intermediate erythroblasts, late erythroblasts, reticulocytes, and erythrocytes comprise HbF.

### Claim 14 (depends on 13)

The method of claim 13, wherein the number of proerythroblasts is decreased or increased.

### Claim 15

(canceled)

### Claim 16 (depends on 7)

The method of claim 7, wherein the number of F cells is increased.

### Claim 17 (depends on 4)

The method of claim 4, wherein the at least one perturbagen selected from Table 3, or a variant thereof, comprises at least 2, at least 3, at least 4, or at least 5 perturbagens selected from Table 3, or variants thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one perturbagen is used in combination with one or more additional therapeutic agents.

### Claim 19 (depends on 18)

The method of claim 18, wherein the additional therapeutic agent is hydroxyurea (HU).

### Claim at position 18

-32. (canceled)

### Claim 33

A method for treating a disease or disorder characterized by an abnormal oxygen delivery, comprising:
(a) administering to a subject in need thereof a therapeutically effective amount of at least one perturbagen selected from Table 3, or a variant thereof, or
(b) administering to a subject in need thereof a cell, the cell having been contacted with at least one perturbagen selected from Table 3, or a variant thereof.

### Claim at position 20

-47. (canceled)

### Claim 48

A method of identifying a candidate perturbation for promoting the transition of a starting population of progenitor cells into erythrocytes comprising HbF or HbF-expressing progenitors thereof, the method comprising:
exposing the starting population of progenitor cells to a perturbation;
identifying a perturbation signature for the perturbation, the perturbation signature comprising one or more cellular-components and a significance score associated with each cellular-component, the significance score of each cellular-component quantifying an association between a change in expression of the cellular-component and a change in cell state of the cells in the population of progenitor cells into erythrocytes comprising HbF or HbF-expressing progenitors thereof following exposure of the population of cells to the perturbation; and
identifying the perturbation as a candidate perturbation for promoting the transition of a population of progenitor cells into erythrocytes comprising HbF or HbF-expressing progenitors thereof based on the perturbation signature,
wherein the perturbation signature is an increase in expression and/or activity in the progenitor cell of one or more genes selected from the genes designated as an “up” gene in the gene directionality column of Table 1a and/or Table 2, and/or a decrease in expression and/or activity in the progenitor cell of one or more genes selected from the genes designated as a “down” gene in the gene directionality column of Table 1a and/or Table 2 and/or an increase in expression and/or activity in the progenitor cell of one or more genes selected from Table 1b and/or a decrease in expression and/or activity in the progenitor cell of one or more genes selected from Table 1b.

### Claim at position 22

-64. (canceled)
